Trial Profile
Multicenter, Open, Pragmatic, Randomized Trial Comparing the Efficacy of 3 Different Lifestyle Interventions After Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 28 Jun 2012 Planned number of patients changed from 1435 to 2500 as reported by European Clinical Trials Database.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Nov 2009 Planned end date changed from 1 Dec 2008 to 1 Nov 2009 as reported by ClinicalTrials.gov.